Why Nektar Therapeutics Shares Are Rallying 13.8% Today
After the company presented results from an early-stage study of its NKTR-214 in solid tumor cancer at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting, Nektar Therapeutics (NASDAQ: NKTR) shares are jumping 13.8% higher as of 2 p.m. EST Monday.
Nektar Therapeutics reported third-quarter financial results that helped shares rally significantly last week, and today, management unveiled promising data from a small phase 1/2 study evaluating NKTR-214 in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Nektar Therapeutics Stock
€1.09
-0.730%
Our community is currently high on Nektar Therapeutics with 3 Buy predictions and 1 Sell predictions.
Based on the current price of 1.09 € the target price of 3 € shows a potential of 175.99% for Nektar Therapeutics which would more than double the current price.
